MedPath

HMI-115: Novel Endometriosis Drug Allows Pregnancy During Treatment

• HMI-115, a new drug for endometriosis, significantly reduces pain and uniquely allows patients to become pregnant during treatment. • The drug works by blocking a protein produced in response to endometriosis, addressing a long-standing need for hormone-bypassing pain relief. • In trials, HMI-115 reduced pain levels by an average of 42% without disrupting the menstrual cycle, offering a significant advantage over existing therapies. • Hope Medicine plans to initiate a larger global trial of HMI-115, potentially offering a new treatment option for the one in ten women affected by endometriosis.

A novel drug, HMI-115, offers new hope for women with endometriosis who wish to conceive. Developed by Hope Medicine, the drug not only alleviates the debilitating pain associated with the condition but also allows patients to pursue pregnancy during treatment, a significant advancement over existing therapies.
Endometriosis, affecting approximately one in ten women, occurs when tissue similar to the uterine lining grows outside the uterus, leading to bleeding, inflammation, and potential infertility. Current treatments often preclude pregnancy, presenting a difficult choice for women desiring children.

Mechanism of Action

HMI-115 functions by inhibiting the production of a specific protein triggered by endometriosis, which is believed to be responsible for the pain experienced by patients. This targeted approach avoids the disruption of sex hormones, a common side effect of other endometriosis drugs like relugolix, which, while effective in reducing symptoms, prevents pregnancy by disrupting the menstrual cycle.

Clinical Trial Results

Clinical trials of HMI-115 have demonstrated promising results, with an average pain reduction of 42%. Crucially, the drug did not appear to disrupt the menstrual cycle, offering a pathway to pregnancy for women undergoing treatment. Professor Rui-Ping Xiao, leading the research at Tsinghua University in Shanghai, emphasized the significance of this development, stating, "For the past 40 years, people have been calling for a new target that provides pain relief while bypassing sex hormones – we are answering that call."

Future Development

Hope Medicine is preparing to launch a larger global trial to further evaluate the efficacy and safety of HMI-115. This expansion reflects the urgent need for innovative endometriosis treatments, as many patients endure diagnostic delays, waiting an average of eight years from symptom onset to diagnosis. Recent NHS guidance has urged GPs to expedite hospital referrals for women with suspected endometriosis to address the issue of missed or delayed diagnoses.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
Endometriosis drug offers hope for sufferers who want children - Daily Mail
dailymail.co.uk · Nov 17, 2024

New endometriosis drug HMI-115 reduces pain by 42% and allows pregnancy during treatment, addressing a long-standing nee...

© Copyright 2025. All Rights Reserved by MedPath